If You Invested in SHL Telemed (SHLT)

SHL Telemedicine Ltd. (NASDAQ: SHLT) is a healthcare technology company engaged in developing and marketing personal telemedicine systems and providing medical call center services. According to the company’s disclosures, SHL focuses on cardiovascular and related diseases, serving both end users and the broader healthcare community. Its services and personal telemedicine devices are offered to subscribers using telephonic and Internet communication technology.

SHL Telemedicine is listed on both the Nasdaq Stock Exchange under the symbol SHLT and the SIX Swiss Exchange under the symbol SHLTN. The company reports operations in several regions, including Israel, the United States and Germany, as reflected in its public communications about revenue contributions and service launches in these markets.

Business focus and core offerings

Across its communications, SHL describes itself as a provider and developer of advanced personal telemedicine solutions centered on cardiac care. A central element of its offering is the SmartHeart® portable 12‑lead ECG technology, which is referenced in multiple announcements. SmartHeart is presented as a user‑friendly, portable ECG device designed to enable high‑quality 12‑lead ECG performance outside traditional clinical settings, including at home, in mobile health units and in other non‑traditional environments.

SHL combines its devices with medical call center services and telemedicine support. The company states that subscribers can transmit ECG data and interact with its telemedicine team via telephonic and Internet communication channels. In various releases, SHL highlights that SmartHeart‑based services can include real‑time guidance, ECG transmission and review, and telehealth interactions with clinicians such as cardiologists, depending on the specific program or partnership.

Telemedicine and cardiac care emphasis

SHL’s public materials consistently emphasize a focus on cardiovascular and related diseases. The company describes offerings that support remote cardiac assessment, monitoring and diagnostics. For example, SHL has announced:

• An at‑home Biomarker blood test service in Israel, guided by SHL’s medical team, designed to rapidly identify cardiac markers for heart attack detection when combined with anamnesis and a 12‑lead ECG transmission.
• Use of SmartHeart technology in randomized clinical research, including the TELE‑ACS trial conducted at Imperial College London, which evaluated post‑acute coronary syndrome (post‑ACS) patients at home.
• Participation of SmartHeart in the U.S. Army’s Project Convergence – Capstone 4 experiment, where the technology was used by healthcare clinicians in field conditions for urgent cardiovascular assessment.

In these contexts, SHL presents SmartHeart as a tool to support rapid evaluation of potential cardiac events, reduce hospital readmissions and emergency department visits in specific study populations, and enable cardiac assessment in settings where traditional equipment may be less accessible.

Geographic footprint and activities

SHL Telemedicine reports activities in several key markets:

• Israel: The company describes Israel as a core operation, referring to B2C and B2B activities and noting that its Israel operation has maintained stability and profitability. SHL has also announced the expansion of its offering in Israel to include at‑home Biomarker blood tests in conjunction with SmartHeart‑based ECG and telemedicine support.
• Germany: SHL has reported the launch and growth of a Doctors’ Virtual Visit service in Germany in collaboration with BARMER, a large health insurer. The company notes that this service is available to millions of insured individuals and is part of its broader telemedicine offering in that market.
• United States: SHL has described significant efforts around direct‑to‑consumer (D2C) sales of the SmartHeart ECG platform and the launch of a SmartHeart® membership program in the U.S. The membership is presented as a private pay program that includes the SmartHeart portable 12‑lead ECG device, 24/7 interpretation by board‑certified cardiologists, and on‑demand telehealth visits. SHL has also highlighted relationships with strategic customers and integration of SmartHeart within CVS Minute Clinics, as well as partnerships with organizations such as DocGo for use in mobile health units.

Partnerships and collaborations

SHL Telemedicine’s announcements describe several collaborations that illustrate how its technology is used:

• A partnership with DocGo Inc., under which DocGo integrates the SmartHeart portable 12‑lead ECG device into its mobile health care units. This collaboration is intended to bring advanced cardiovascular diagnostics to patients’ homes and underserved communities, initially in the New York–New Jersey area and then in additional U.S. markets, including a first phase focused on California.
• Clinical collaborations with institutions such as Imperial College London and the Mayo Clinic, where SmartHeart has been evaluated in clinical studies related to post‑ACS patient care and remote cardiac monitoring.
• Participation in the U.S. Army’s Project Convergence – Capstone 4 experiment, where SmartHeart was used in a multi‑day army medical experiment at the National Training Center in the Mojave Desert.

These collaborations are presented by SHL as evidence of how its telemedicine systems and SmartHeart technology can be deployed in diverse healthcare settings, from home environments to military field operations.

Regulatory status and listings

SHL Telemedicine states that it is listed on the SIX Swiss Exchange (ticker SHLTN, ISIN IL0010855885, Security No. 1128957) and on the Nasdaq Stock Exchange (ticker SHLT, ISIN US78423T2006, CUSIP 78423T200). The company files reports as a foreign private issuer, including Form 6‑K current reports furnished under the Securities Exchange Act of 1934. Recent Form 6‑K filings reference press releases about financial results and corporate actions.

Research coverage and market perception

In one announcement, SHL Telemedicine reports that an equity research firm initiated coverage of the company with a particular rating and price target, describing SHL as a pure‑play participant in the telemedicine market and noting its experience and telehealth monitoring capabilities. These characterizations are attributed to the external research firm and are presented by SHL as part of its investor communications.

Clinical evidence and telemedicine impact

SHL highlights clinical evidence related to its technology. The TELE‑ACS trial conducted at a tertiary center in London evaluated SmartHeart in post‑ACS patients at home, with results presented at a major cardiology conference and published in the Journal of the American College of Cardiology. The company reports that the trial showed reductions in hospital readmissions and emergency department visits, as well as reductions in certain patient‑reported symptoms, for patients using telemedicine compared to standard care.

Additionally, SHL references clinical studies from the Mayo Clinic and Imperial College London that, according to the company, support SmartHeart’s potential to reduce emergency visits and readmission rates in specific cardiac patient populations. These findings are cited by SHL as supporting its focus on remote cardiac care.

Investor information and reporting

SHL Telemedicine communicates with investors through press releases, conference calls and reports. The company has announced annual results, financial highlights and strategic developments, including revenue contributions by region, investments in markets such as Germany and the U.S., and information on cash balances and profitability. It has also referenced the availability of its full‑year reports and presentations on public platforms and through SEC submissions.

As a foreign private issuer listed on Nasdaq, SHL furnishes Form 6‑K reports that include press releases on topics such as financial results and invitations to shareholder meetings. These filings provide additional context on the company’s operations, strategic priorities and capital market activities.

Summary

According to its public disclosures, SHL Telemedicine Ltd. is focused on personal telemedicine systems and medical call center services with an emphasis on cardiovascular care. Through its SmartHeart portable 12‑lead ECG technology, telemedicine services and partnerships, the company positions itself in remote cardiac assessment and monitoring across multiple geographies. Its dual listings on Nasdaq and the SIX Swiss Exchange, clinical collaborations and ongoing investor reporting form the core of the information available to market participants researching SHLT stock.